Key Takeaways
- Shares of BSX declined 9% to close at $62.93, marking the weakest finish since January 2024
- CHAMPION-AF trial results demonstrated non-inferiority for the Watchman FLX versus anticoagulants, though a 3.2% ischemic stroke rate compared to 2% concerned market participants
- Raymond James lowered its rating from Strong Buy to Outperform while reducing the price objective from $97 to $88
- The rating adjustment reflected decelerating momentum in U.S. electrophysiology and Watchman segments, which represented over 50% of the company’s annual growth
- Year-to-date, BSX has retreated 34%, substantially worse than the S&P 500’s 7.1% downturn
Boston Scientific experienced significant pressure on Monday following a dual setback: clinical trial findings that disappointed investors and a Wall Street analyst rating reduction.
Boston Scientific Corporation, BSX
Data from the CHAMPION-AF clinical study evaluating the Watchman FLX device was unveiled at a medical gathering on March 30. The headline results appeared favorable at first glance. The device achieved non-inferiority when compared against contemporary anticoagulation therapies such as Eliquis and Xarelto. Additionally, Watchman patients experienced lower rates of non-procedural bleeding, successfully meeting the trial’s main objective.
However, market participants fixated on a particular metric. The ischemic stroke incidence among Watchman recipients reached 3.2%, while patients receiving blood thinners experienced a 2% rate. This differential, though modest, triggered notable investor anxiety.
It merits emphasis that this variance lacked statistical significance. Furthermore, it wasn’t designated as a primary study endpoint. The research team intends to monitor participants over a five-year period to obtain more comprehensive stroke risk data.
Medical Experts Challenge Market Reaction
Study co-chair Marty Leon characterized the findings as “a very strong endorsement” for broader device utilization. He articulated the risk-benefit calculation plainly: an annualized 0.33% elevation in stroke or embolization compared against an approximately 2.6% decrease in bleeding events. Boston Scientific’s chief medical officer, Ken Stein, reinforced this perspective, emphasizing that stroke occurrences in both cohorts were “incredibly low.”
Truist Securities observed that overall conference sentiment remained favorable. Leerink Partners indicated that firsthand reactions strengthened their outlook that the trial outcomes would drive increased Watchman procedure volumes moving forward.
Nevertheless, market sentiment proved unforgiving. BSX settled at $62.93, representing its weakest closing price since January 30, 2024.
Concurrently, Raymond James reduced BSX from Strong Buy to Outperform while lowering its price target from $97 to $88. The investment firm highlighted weakening performance in two critical expansion areas: U.S. electrophysiology and Watchman, which collectively represented 26% of 2025 revenue and contributed over half the company’s annual growth.
Raymond James Maintains Positive View Despite Estimate Reductions
Raymond James analyst Jayson Bedford clarified that the downgrade didn’t signal fundamental concern. The firm continues to regard Boston Scientific as among the highest-quality, fastest-expanding enterprises within large-cap medical device technology. The rating modification reflected diminished near-term certainty rather than altered long-term prospects.
The firm reduced its 2026 and 2027 revenue projections by approximately 0.5% and 1.5% respectively. Watchman growth is now modeled at 17% and 16% for the upcoming two years, revised downward from prior expectations of 18% and 20%. Electrophysiology growth assumptions were adjusted to 15% and 14%.
Notwithstanding these adjustments, Raymond James contended the valuation remains compelling. BSX currently trades around 18 times anticipated 2027 earnings, compared with a 21 times multiple for industry peers.
Multiple other research firms — including Bernstein, Evercore ISI, Stifel, Truist, and Jefferies — maintain Buy or Outperform recommendations, with price objectives spanning $88 to $120.
BSX has declined 34% year-to-date. The shares reached a 52-week peak of $110 earlier this year.
